symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
GMDA,0.8867,1.545454,1214071,116269424,0,0.56-2.51,-0.0001,Gamida Cell Ltd.,USD,0001600847,IL0011552663,M47364100,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.gamida-cell.com,"Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.",Ms. Abigail L. Jenkins,Healthcare,IL,143,972 2 659 5666,5 Nahum Heftsadie Street,Jerusalem,,91340,1.43614,3.05614,https://financialmodelingprep.com/image-stock/GMDA.png,2018-10-26,False,False,True,False,False
